Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ARTIVION, INC.

(AORT)
  Report
Delayed Nyse  -  04:00 2022-11-30 pm EST
12.79 USD   +5.70%
11/09Artivion, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
11/08Artivion to Participate in Upcoming Investor Conferences
PR
11/04ARTIVION, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Artivion Follows Recommendation to Stop PROACT Xa Clinical Trial

09/23/2022 | 07:00am EST

Artivion, Inc. announced that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin. The decision was based on the recommendation of the independent Data and Safety Monitoring Board (DSMB) of the trial due to lack of evidence supporting non-inferiority of apixaban to warfarin for valve thrombosis and thromboembolism. The PROACT Xa trial randomized patients having an On-X aortic valve replacement to receive either warfarin or apixaban as their anticoagulant to prevent blood clots.

The trial began enrolling in April 2020. The DSMB found that blood clots, resulting in stroke, occurred more frequently in patients receiving apixaban and that continuing the trial was unlikely to achieve the primary endpoint while possibly exposing patients to increased risk. Physician investigators at the trial's sites are being notified to change patients who are in the apixaban arm of the trial back to warfarin.


ę S&P Capital IQ 2022
All news about ARTIVION, INC.
11/09Artivion, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
11/08Artivion to Participate in Upcoming Investor Conferences
PR
11/04ARTIVION, INC. Management's Discussion and Analysis of Financial Condition and Results..
AQ
11/04Needham Adjusts Price Target on Artivion to $23 From $28, Maintains Buy Rating
MT
11/03Artivion : Q3 Earnings Snapshot
AQ
11/03Artivion, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022
CI
11/03Transcript : Artivion, Inc., Q3 2022 Earnings Call, Nov 03, 2022
CI
11/03Earnings Flash (AORT) ARTIVION Reports Q3 Revenue $76.8M, vs. Street Est of $76.2M
MT
11/03Earnings Flash (AORT) ARTIVION Reports Q3 Loss $-0.05, vs. Street Est of $-0.05
MT
11/03Artivion, Inc. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Analyst Recommendations on ARTIVION, INC.
More recommendations
Financials (USD)
Sales 2022 315 M - -
Net income 2022 -27,2 M - -
Net Debt 2022 276 M - -
P/E ratio 2022 -19,5x
Yield 2022 -
Capitalization 516 M 516 M -
EV / Sales 2022 2,52x
EV / Sales 2023 2,38x
Nbr of Employees 1 300
Free-Float 89,0%
Chart ARTIVION, INC.
Duration : Period :
Artivion, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARTIVION, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 12,79 $
Average target price 23,13 $
Spread / Average Target 80,8%
EPS Revisions
Managers and Directors
James Patrick Mackin Chairman, President & Chief Executive Officer
David Ashley Lee Chief Operating & Financial Officer, Executive VP
Scott B. Capps Vice President-Clinical Research
Franz Peter Barthold Vice President-Research & Development
Marshall S. Stanton Chief Medical Officer & SVP-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
ARTIVION, INC.-37.15%516
ABBOTT LABORATORIES-25.39%183 075
MEDTRONIC PLC-26.07%101 730
BECTON, DICKINSON AND COMPANY-1.93%68 299
DEXCOM, INC.-13.38%42 639
HOYA CORPORATION-16.07%36 984